CN103690538A - Traditional Chinese medicine extract and traditional Chinese medicine composition having poultry and livestock mycoplasma resistant activity - Google Patents
Traditional Chinese medicine extract and traditional Chinese medicine composition having poultry and livestock mycoplasma resistant activity Download PDFInfo
- Publication number
- CN103690538A CN103690538A CN201310642170.5A CN201310642170A CN103690538A CN 103690538 A CN103690538 A CN 103690538A CN 201310642170 A CN201310642170 A CN 201310642170A CN 103690538 A CN103690538 A CN 103690538A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- mycoplasma
- radix
- medicine extract
- fowl poultry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 117
- 241000204031 Mycoplasma Species 0.000 title claims abstract description 78
- 244000144977 poultry Species 0.000 title claims abstract description 57
- 230000000694 effects Effects 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 244000144972 livestock Species 0.000 title abstract description 8
- QLDAACVSUMUMOR-UHFFFAOYSA-M 2,3-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride Chemical compound [Cl-].C1=C2C3=[N+](C)C=C4C=C(OC)C(OC)=CC4=C3C=CC2=CC2=C1OCO2 QLDAACVSUMUMOR-UHFFFAOYSA-M 0.000 claims abstract description 35
- INVGWHRKADIJHF-UHFFFAOYSA-N Sanguinarin Chemical compound C1=C2OCOC2=CC2=C3[N+](C)=CC4=C(OCO5)C5=CC=C4C3=CC=C21 INVGWHRKADIJHF-UHFFFAOYSA-N 0.000 claims abstract description 34
- LLEJIEBFSOEYIV-UHFFFAOYSA-N chelerythrine Chemical compound C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 LLEJIEBFSOEYIV-UHFFFAOYSA-N 0.000 claims abstract description 22
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims abstract description 18
- RATMHCJTVBHJSU-UHFFFAOYSA-N Dihydrochelerythrine Natural products C1=C2OCOC2=CC2=C(N(C)C(O)C=3C4=CC=C(C=3OC)OC)C4=CC=C21 RATMHCJTVBHJSU-UHFFFAOYSA-N 0.000 claims abstract description 17
- FCEXWTOTHXCQCQ-UHFFFAOYSA-N Ethoxydihydrosanguinarine Natural products C12=CC=C3OCOC3=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 FCEXWTOTHXCQCQ-UHFFFAOYSA-N 0.000 claims abstract description 17
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960003720 enoxolone Drugs 0.000 claims abstract description 17
- 229940084560 sanguinarine Drugs 0.000 claims abstract description 17
- YZRQUTZNTDAYPJ-UHFFFAOYSA-N sanguinarine pseudobase Natural products C1=C2OCOC2=CC2=C3N(C)C(O)C4=C(OCO5)C5=CC=C4C3=CC=C21 YZRQUTZNTDAYPJ-UHFFFAOYSA-N 0.000 claims abstract description 17
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 claims abstract description 16
- OXEZOWCIRUNPIN-UHFFFAOYSA-N Chelerythrin-pseudoethanolat Natural products C12=CC=C(OC)C(OC)=C2C(OCC)N(C)C(C2=C3)=C1C=CC2=CC1=C3OCO1 OXEZOWCIRUNPIN-UHFFFAOYSA-N 0.000 claims abstract description 14
- KRFBMPVGAYGGJE-UHFFFAOYSA-N nevadensin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C(OC)=C(O)C(OC)=C2O1 KRFBMPVGAYGGJE-UHFFFAOYSA-N 0.000 claims abstract description 14
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 claims abstract description 12
- FPJQGFLUORYYPE-UHFFFAOYSA-N epiberberine Chemical compound C1=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C2OCOC2=C1 FPJQGFLUORYYPE-UHFFFAOYSA-N 0.000 claims abstract description 12
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 claims abstract description 12
- XYHOBCMEDLZUMP-UHFFFAOYSA-N coptisine Chemical compound C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 XYHOBCMEDLZUMP-UHFFFAOYSA-N 0.000 claims abstract 5
- 150000001875 compounds Chemical class 0.000 claims description 28
- 239000007788 liquid Substances 0.000 claims description 27
- 241000287828 Gallus gallus Species 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 17
- 229940079593 drug Drugs 0.000 claims description 16
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 14
- 241001138504 Mycoplasma bovis Species 0.000 claims description 7
- 241001148556 Mycoplasma ovipneumoniae Species 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 abstract description 16
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- 201000010099 disease Diseases 0.000 abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
- WEEFNMFMNMASJY-UHFFFAOYSA-M 1,2-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride Chemical compound [Cl-].C1=C2OCOC2=CC2=CC=C3C4=CC=C(OC)C(OC)=C4C=[N+](C)C3=C21 WEEFNMFMNMASJY-UHFFFAOYSA-M 0.000 description 12
- LUXPUVKJHVUJAV-UHFFFAOYSA-M coptisine, chloride Chemical compound [Cl-].C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 LUXPUVKJHVUJAV-UHFFFAOYSA-M 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000001914 filtration Methods 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 239000012982 microporous membrane Substances 0.000 description 9
- 239000012153 distilled water Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 238000003809 water extraction Methods 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 5
- 239000007640 basal medium Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000003285 pharmacodynamic effect Effects 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 3
- 241000857725 Mycoplasma bovis PG45 Species 0.000 description 3
- 241001193060 Mycoplasma ovipneumoniae ATCC 29419 Species 0.000 description 3
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 235000004237 Crocus Nutrition 0.000 description 2
- 241000596148 Crocus Species 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 208000018569 Respiratory Tract disease Diseases 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000001088 anti-asthma Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002725 anti-mycoplasma Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003640 drug residue Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- -1 polypropylene Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 102000008482 12E7 Antigen Human genes 0.000 description 1
- 108010020567 12E7 Antigen Proteins 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000012353 Contagious Pleuropneumonia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 1
- 101000692878 Homo sapiens Regulator of MON1-CCZ1 complex Proteins 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 206010028470 Mycoplasma infections Diseases 0.000 description 1
- 241000202936 Mycoplasma mycoides Species 0.000 description 1
- 241000123119 Mycoplasma mycoides subsp. capri Species 0.000 description 1
- 241000204003 Mycoplasmatales Species 0.000 description 1
- KKMPSGJPCCJYRV-UHFFFAOYSA-N Nitidine Natural products C1=C2C3=[N+](C)C=C4C=C(OC)C(OC)=CC4=C3C=CC2=CC2=C1OCO2 KKMPSGJPCCJYRV-UHFFFAOYSA-N 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 102100026436 Regulator of MON1-CCZ1 complex Human genes 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 201000006509 pleuropneumonia Diseases 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a traditional Chinese medicine extract having poultry and livestock mycoplasma resistant activity. The traditional Chinese medicine extract contains any one or more of the following components: 1-512 mu g/mL of nitidine chloride, 1-512 mu g/mL of ethoxychelerythrine, 1-512 mu g/mL of chelerythrine, 1-512 mu g/mL of sanguinarine, 1-512 mu g/mL of coptisine, 1-512 mu g/mL of palmatine, 1-512 mu g/mL of epiberberine, and 1-512 mu g/mL of glycyrrhetinic acid. The invention further provides a traditional Chinese medicine composition having poultry and livestock mycoplasma resistant activity. Both the traditional Chinese medicine extract and the traditional Chinese medicine composition provided by the invention have the stronger effect for inhibiting poultry and livestock mycoplasma activity in vitro, are safe, green and free from medicine residue, and can be applied to treating and preventing poultry and livestock mycoplasma diseases.
Description
Technical field
The present invention relates to have Chinese medicine extract and the Chinese medicine composition of anti-fowl poultry mycoplasma activity.
Background technology
Along with constantly soaring to the demand of fowl poultry of people, the quantity of livestock culture industry also constantly increases, yet the fowl poultry mycoplasma being caused by fowl poultry mycoplasma infection has also become more common in recent years disease.The chicken chronic respiratory tract disease that this wherein causes with chicken virus mycoplasma, these three kinds of diseases of the goats contagious pleuropneumonia that the pulmonis Bovis seu Bubali disease that mycoplasma mycoides subsp (Mycoplasma bovis) causes and Mycoplasma mycoides subsp.capri (mycoplasma ovipneumoniae) cause are comparatively serious, caused huge economic loss to livestock culture industry.
At present, prevention and treatment fowl poultry mycoplasma are mainly to adopt antibiotics, yet due to antibiotic abuse in recent years, the ratio of Resistant strain also rises year by year, and the drug resistance phenomenon of generation is more and more serious, and its therapeutic effect is unsatisfactory.
Summary of the invention
In view of this, be necessary to provide a kind of Chinese medicine extract with anti-fowl poultry mycoplasma activity.
In addition, be also necessary to provide a kind of Chinese medicine composition with anti-fowl poultry mycoplasma activity.
A kind of Chinese medicine extract with anti-fowl poultry mycoplasma activity, this Chinese medicine extract contains nitidine chloride, ethoxychelerythrine, chelerythrine, Sanguinarine, coptisine, palmatine, any one in epiberberine and enoxolone or multiple, the content range of each material is: nitidine chloride 1-512 μ g/mL, ethoxychelerythrine 1-512 μ g/mL, chelerythrine 1-512 μ g/mL, Sanguinarine 1-512 μ g/mL, coptisine 1-512 μ g/mL, palmatine 1-512 μ g/mL, epiberberine 1-512 μ g/mL and enoxolone 1-512 μ g/mL.
A kind of Chinese medicine composition with anti-fowl poultry mycoplasma activity, the crude drug that described Chinese medicine composition comprises following proportioning: at least one of 0-5g in Radix Zanthoxyli 0-10g, Rhizoma Coptidis 0-10g, Cortex Phellodendri 0-10g and Radix Glycyrrhizae, and at least one in Rhizoma Et Radix Baphicacanthis Cusiae 0-30g, Herba Pogostemonis 0-15g, Radix Scutellariae 0-10g, Cortex Dictamni 0-20g, Cortex Pseudolaricis 0-5g, Folium Artemisiae Argyi 0-5g.
Chinese medicine extract and the Chinese medicine composition of anti-fowl poultry mycoplasma activity provided by the invention have heat-clearing and toxic substances removing, heat clearing and damp drying effect, fowl poultry mycoplasma activity is had to obvious inhibition, there is good antipyretic, analgesia, antiinflammatory, cough-relieving, reduce phlegm and antiasthmatic effect, can effectively alleviate the respiratory symptom that fowl poultry mycoplasma causes, and Chinese medicine extract provided by the invention is to extract and make from Chinese medicine, itself and Chinese medicine composition all have safe green no drug residue advantage, and this is that antibiotic etc is incomparable.
The specific embodiment
The main theory of the disease that treatment is caused by fowl poultry mycoplasma is according to there being 3 points: the first, heat-clearing and toxic substances removing and blood circulation promoting and blood stasis dispelling; The second, purging FU-organs lung qi dispersing, purging liver-fire; Three, clear ripe removing toxic substances, the pure expectorant of lung qi dispersing.Therefore, treat the Chinese medicine that fowl poultry mycoplasma need to have heat-clearing and toxic substances removing and heat clearing and damp drying effect, the Chinese medicines such as compatibility Rhizoma Coptidis, Radix Scutellariae, Cortex Phellodendri, Radix Glycyrrhizae, Cortex Dictamni, Cortex Pseudolaricis, Folium Artemisiae Argyi such as southern medicine Radix Zanthoxyli, Herba Pogostemonis, Rhizoma Et Radix Baphicacanthis Cusiae.
The present invention's separation from above-mentioned Chinese medicine obtains plurality of Chinese extract, and by adopting two times of serial dilution methods of 96 orifice plate to obtain, has the Chinese medicine extract of anti-fowl poultry mycoplasma activity.China is the native place of Chinese herbal medicine, Chinese medicine resources of medicinal plant is very abundant, adopt Chinese herb prevention fowl poultry mycoplasma to there is the Chinese medicine status can not be ignored, and the separated Chinese medicine extract obtaining has other antibiotic or the irreplaceable advantage of chemicals from Chinese medicine, as there is little, the difficult drug resistance etc. that produces of toxic and side effects.
Described Chinese medicine extract contain in nitidine chloride, ethoxychelerythrine, chelerythrine, Sanguinarine, coptisine, palmatine, epiberberine and enoxolone any one or multiple, the content range of each material is: nitidine chloride 1-512 μ g/mL, ethoxychelerythrine 1-512 μ g/mL, chelerythrine 1-512 μ g/mL, Sanguinarine 1-512 μ g/mL, coptisine 1-512 μ g/mL, palmatine 1-512 μ g/mL, epiberberine 1-512 μ g/mL and enoxolone 1-512 μ g/mL.
In above-mentioned Chinese medicine extract, described enoxolone is from Radix Glycyrrhizae, and described coptisine, palmatine and epiberberine are from Rhizoma Coptidis and Cortex Phellodendri, and described nitidine chloride, ethoxychelerythrine, chelerythrine and Sanguinarine are all from Radix Zanthoxyli.
The inhibition of described Chinese medicine extract In Vitro Anti fowl poultry mycoplasma activity is different, wherein, these four kinds of Chinese medicine extract of nitidine chloride, ethoxychelerythrine, chelerythrine and Sanguinarine all have stronger In-vitro Inhibitory Effect to this 3 mycoplasma species of chicken virus mycoplasma, Mycoplasma bovis and mycoplasma ovipneumoniae, and these four kinds of Chinese medicine extract of coptisine, palmatine, epiberberine and enoxolone only have stronger In-vitro Inhibitory Effect to chicken virus mycoplasma.
Described Chinese medicine extract can be applied in separately in the systemic disease medicines such as the caused cattle for the treatment of fowl poultry mycoplasma, sheep, chicken, also can, according to the active situation of described Chinese medicine extract In Vitro Anti fowl poultry mycoplasma, the mutual applied in any combination of above-mentioned different Chinese medicine extract be raiseeed in the systemic disease medicines such as the caused cattle of mycoplasma, sheep, chicken treatment fowl.The fowl poultry mycoplasma that for example combination of the combination of the combination of nitidine chloride and ethoxychelerythrine, nitidine chloride and chelerythrine, nitidine chloride and Sanguinarine can cause chicken virus mycoplasma, Mycoplasma bovis and mycoplasma ovipneumoniae is prevented or treats; The chicken chronic respiratory tract disease that the combination of nitidine chloride and enoxolone can cause chicken virus mycoplasma is prevented or treats.
Wherein, preferred Chinese medicine extract is following five kinds of combinations, its respectively:
Combination one: nitidine chloride 1 μ g/mL, ethyoxyl Herba Chelidonii 8 μ g/mL;
Combination two: nitidine chloride 1 μ g/mL, chelerythrine 4 μ g/mL;
Combination three: nitidine chloride 2 μ g/mL, Sanguinarine 2 μ g/mL;
Combination four: nitidine chloride 1 μ g/mL, enoxolone 1 μ g/mL;
Combination five: nitidine chloride 1 μ g/mL, coptisine 4 μ g/mL.
Described Chinese medicine extract can be prepared into the preparation for the treatment of or prevention fowl poultry mycoplasma, and described preparation can be any one dosage forms such as injection, spray, granule, oral liquid, pill, powder.
The present invention also provides the Chinese medicine composition with anti-fowl poultry mycoplasma activity, the crude drug that described Chinese medicine composition comprises following proportioning: at least one of 0-5g in Radix Zanthoxyli 0-10g, Rhizoma Coptidis 0-10g, Cortex Phellodendri 0-10g and Radix Glycyrrhizae, and at least one in Rhizoma Et Radix Baphicacanthis Cusiae 0-30g, Herba Pogostemonis 0-15g, Radix Scutellariae 0-10g, Cortex Dictamni 0-20g, Cortex Pseudolaricis 0-5g, Folium Artemisiae Argyi 0-5g.
Preferred Chinese medicine composition is following 7 kinds of compound recipes, its respectively:
Compound recipe 1: Rhizoma Et Radix Baphicacanthis Cusiae 30g, Radix Zanthoxyli 10g;
Compound recipe 2: Rhizoma Et Radix Baphicacanthis Cusiae 30g, Radix Zanthoxyli 10g, Radix Glycyrrhizae 5g;
Compound recipe 3: Rhizoma Et Radix Baphicacanthis Cusiae 30g, Radix Zanthoxyli 10g, Rhizoma Coptidis 10g, Cortex Phellodendri 10g;
Compound recipe 4: Rhizoma Et Radix Baphicacanthis Cusiae 30g, Radix Zanthoxyli 10g, Radix Scutellariae 10g;
Compound recipe 5: Rhizoma Et Radix Baphicacanthis Cusiae 30g, Radix Zanthoxyli 10g, Cortex Dictamni 20g;
Compound recipe 6: Rhizoma Et Radix Baphicacanthis Cusiae 30g, Radix Zanthoxyli 10g, Cortex Dictamni 20g, Rhizoma Coptidis 10g, Cortex Phellodendri 10g;
Compound recipe 7: Rhizoma Coptidis 10g, Radix Scutellariae 10g, Cortex Phellodendri 10g, Radix Glycyrrhizae 5g;
Wherein more preferred with compound recipe 3, compound recipe 5 and compound recipe 6.
Understandable, described Chinese medicine composition can be prepared into the preparation for the treatment of or prevention fowl poultry mycoplasma, and described preparation can be any one dosage forms such as injection, spray, granule, oral liquid, pill, powder.
Below by concrete pharmacodynamic experiment, Chinese medicine extract provided by the invention is specifically described.
1. experiment bacterial strain
Mycoplasma bovis PG45 strain, chicken virus mycoplasma (MG) Bc44T strain and mycoplasma ovipneumoniae Y-98 strain provide by Jilin University's Zoonosis institute.
2. medicine
From Radix Zanthoxyli, Rhizoma Coptidis, Cortex Phellodendri and Radix Glycyrrhizae four taste Chinese medicines, extract Chinese medicine extract nitidine chloride, ethoxychelerythrine, chelerythrine, Sanguinarine, coptisine, palmatine, epiberberine and enoxolone, purity all reaches 99.9%.Above-mentioned 8 kinds of Chinese medicine extract are used respectively to DMSO(dimethyl sulfoxide, dimethyl sulfoxide) Chinese medicine extract is made into the mother liquid medicine that final concentration is 40960 μ g/ml, the aseptic polypropylene centrifuge tube of subpackage 1.5mL, with sealed membrane sealing, sealing is stored at-60 ℃ or lower temperature.
3. culture medium
KM
2the preparation of (Mycoplasma hyopneu-nK nlae Medium) basal medium: to adding the required things such as appropriate horse serum, 0.4% phenol red and penicillin in KM2 basal medium, adjust pH value to 7.6,0.22 μ m filtering with microporous membrane degerming, obtains, and 4 ℃ save backup.
PPLO (pleuropneumonia-like organis, tissue culture pollutes l organisms) preparation of basal medium: to adding the required things such as appropriate Ox blood serum, 0.4% phenol red and penicillin in PPLO basal medium, adjust pH value to 7.8,0.22 μ m filtering with microporous membrane degerming, obtain, 4 ℃ save backup.
4. the preparation of work bacterium liquid:
The strain of lyophilizing standard mycoplasma is added in corresponding basal medium, and Mycoplasma bovis PG45 strain is added in PPLO culture medium, and chicken virus mycoplasma (MG) Bc44T strain and mycoplasma ovipneumoniae Y-98 strain are added to respectively in KM2 culture medium, put 37 ℃, 5%CO
2in incubator, cultivate 7 days, make its continuous passage, get third generation logarithmic growth bacterium liquid, wherein, Mycoplasma bovis PG45 strain is 1 * 10
8cCU/mL, chicken virus mycoplasma Bc44T strain are 1 * 10
9cCU/mL, mycoplasma ovipneumoniae Y-98 strain are 1 * 10
10cCU/mL, is diluted to 1 * 10 by respective liquid culture medium
4cCU/ml, as work bacterium liquid.
5.MIC(Minimum inhibitory concentration, minimal inhibitory concentration) pH-value determination pH:
Get aseptic 96 porocyte culture plates, in every the 1st hole of arranging, add culture medium 195 μ L, 2nd～12 holes add culture medium 100 μ L; Then to the 1st hole, add mother liquid medicine 5 μ L, and with micro sample adding appliance since the 1st doubling dilution medicinal liquid to the 10 holes, hole, after mixing, in the 10th hole sucking-off 100 μ L, discard; Then 1st～11 holes add respectively work bacterium liquid 100 μ L, and making porose total liquid volume is 200 μ L, the 11st positive control wells in hole (being growth control hole), the 12nd negative control wells in hole; The final concentration of medicine is followed successively by (unit: μ g/mL) 512.00,256.00,128.00,64.00,32.00,16.00,8.00,4.00,2.00,1.00 from 1st～10, totally 10 are diluted gradients, splash into the sealing of sterile liquid paraffin oil, cover plate lid, put interior 37 ℃ of constant incubator, 5%CO
2cultivate 3～4 days.
According to culture medium change color result of determination: culture medium explanation when redness becomes yellow or crocus has mycoplasma to grow.Cultivate observed result after 3～4 days, during when positive control hole generation color change (being that in culture fluid, phenol red indicator becomes yellow or crocus from redness) and without muddiness, medicine feeding hole no longer occurs that the minimum drug level of change color is the minimum mycoplasma growth concentration (MIC) that effectively suppresses.Experiment repeats 6 times, gets the meansigma methods of 6 results.The concrete ginseng of the MIC value table one of the In Vitro Anti fowl poultry mycoplasma of 8 kinds of Chinese medicine extract:
Table one
At present, judgement to the minimal inhibitory concentration (MIC) of monomeric compound or antibiotics anti-mycoplasma both at home and abroad, according to the criterion of similar experiment bibliographical information, be according to judging, comparatively responsive while being MIC≤4 μ g/mL, when MIC is 4～32 μ g/mL, be medium sensitivity, be insensitive when the μ g/mL of MIC >=32.
As shown in Table 1: above-mentioned 8 kinds of Chinese medicine extract all have the inhibition of good In Vitro Anti fowl poultry mycoplasma activity, enoxolone wherein, only to chicken virus mycoplasma (MG) Bc44T, strain has stronger In-vitro Inhibitory Effect to these 4 Chinese medicine extract of coptisine, palmatine and epiberberine; Nitidine chloride, ethoxychelerythrine, chelerythrine and Sanguinarine all have stronger In-vitro Inhibitory Effect to the 3 mycoplasma species strains of this experiment.
Below by concrete pharmacodynamic experiment, the combination of Chinese medicine extract provided by the invention is specifically described.
Combination one:
Preparation is combined by 1 part of nitidine chloride and 8 parts of Chinese medicine extract that form of ethyoxyl Herba Chelidonii, and it is mixed with to final concentration with DMSO, and to be respectively the medicinal liquid of 1 μ g/mL and 8 μ g/mL standby.
Combination two:
Preparation is combined by 1 part of nitidine chloride and 4 parts of Chinese medicine extract that form of chelerythrine, and it is mixed with to final concentration with DMSO, and to be respectively the medicinal liquid of 1 μ g/mL and 4 μ g/mL standby.
Combination three:
Preparation is combined by 2 parts of nitidine chlorides and 2 parts of Chinese medicine extract that form of Sanguinarine, and it is mixed with to final concentration with DMSO, and to be the medicinal liquid of 2 μ g/mL standby.
Combination four:
Preparation is combined by 1 part of nitidine chloride and 1 part of Chinese medicine extract forming of enoxolone, and it is mixed with to final concentration with DMSO, and to be the medicinal liquid of 1 μ g/mL standby.
Combination five:
Preparation is combined by 1 part of nitidine chloride and 4 parts of Chinese medicine extract that form of coptisine, and it is mixed with to final concentration with DMSO, and to be respectively the medicinal liquid of 1 μ g/mL and 4 μ g/mL standby.
Above-mentioned five kinds of combinations being made to medicinal liquid and carry out pharmacodynamic experiment, is also the MIC value of utilizing the anti-fowl poultry of measuring in vitro of two times of serial dilution methods of 96 orifice plate mycoplasma, and assay method is the same.The MIC value of the In Vitro Anti fowl poultry mycoplasma of described five groups of combinations specifically please be joined table two.
Table two
By table two, learnt: the combination of the combination of the combination of nitidine chloride and ethoxychelerythrine, nitidine chloride and chelerythrine, nitidine chloride and Sanguinarine all has stronger In-vitro Inhibitory Effect to the 3 mycoplasma species strains of this experiment; Only to chicken virus mycoplasma (MG) Bc44T, strain has stronger In-vitro Inhibitory Effect in the combination of the combination of nitidine chloride and enoxolone, nitidine chloride and coptisine.
Below by concrete pharmacodynamic experiment, Chinese medicine composition provided by the invention is specifically described.
Compound recipe one:
Get Rhizoma Et Radix Baphicacanthis Cusiae 30g, Radix Zanthoxyli 10g, add 10 times of amount distilled water, soak 0.5h, reflux, extract, 3 times, each 1h, merges 3 times extracting solution, quantitatively filter, being concentrated into 10mL(is that every 1mL water extraction liquid is equivalent to containing crude drug amount 2g), finally adopt after 0.22 μ m filtering with microporous membrane standby.
Compound recipe two:
Get Rhizoma Et Radix Baphicacanthis Cusiae 30g, Radix Zanthoxyli 10g, Radix Glycyrrhizae 5g, add 10 times of amount distilled water, soak 0.5h, reflux, extract, 3 times, each 1h, merges 3 times extracting solution, quantitatively filter, be concentrated into 10mL, (be every 1mL water extraction liquid be equivalent to containing crude drug amount 2g), finally adopts after 0.22 μ m filtering with microporous membrane standby.
Compound recipe three:
Get Rhizoma Et Radix Baphicacanthis Cusiae 30g, Radix Zanthoxyli 10g, Rhizoma Coptidis 10g, Cortex Phellodendri 10g, add 10 times of amount distilled water, soak 0.5h, reflux, extract, 3 times, each 1h, merges 3 times extracting solution, quantitatively filters, being concentrated into 10mL(and being every 1mL water extraction liquid is equivalent to containing crude drug amount 2g), finally adopt after 0.22 μ m filtering with microporous membrane standby.
Compound recipe four:
Get Rhizoma Et Radix Baphicacanthis Cusiae 30g, Radix Zanthoxyli 10g, Radix Scutellariae 10g, add 10 times of amount distilled water, soak 0.5h, reflux, extract, 3 times, each 1h, merges 3 times extracting solution, quantitatively filters, being concentrated into 10mL(and being every 1mL water extraction liquid is equivalent to containing crude drug amount 2g), finally adopt after 0.22 μ m filtering with microporous membrane standby.
Compound recipe five:
Get Rhizoma Et Radix Baphicacanthis Cusiae 30g, Radix Zanthoxyli 10g, Cortex Dictamni 20g, add 10 times of amount distilled water, soak 0.5h, reflux, extract, 3 times, each 1h, merges 3 times extracting solution, quantitatively filters, being concentrated into 10mL(and being every 1mL water extraction liquid is equivalent to containing crude drug amount 2g), finally adopt after 0.22 μ m filtering with microporous membrane standby.
Compound recipe six:
Get Rhizoma Et Radix Baphicacanthis Cusiae 30g, Radix Zanthoxyli 10g, Cortex Dictamni 20g, Rhizoma Coptidis 10g, Cortex Phellodendri 10g, add 10 times of amount distilled water, soak 0.5h, reflux, extract, 3 times, each 1h, merges 3 times extracting solution, quantitatively filters, being concentrated into 10ml(and being every 1mL water extraction liquid is equivalent to containing crude drug amount 2g), finally adopt after 0.22 μ m filtering with microporous membrane standby.
Compound recipe seven:
Get Rhizoma Coptidis 10g, Radix Scutellariae 10g, Cortex Phellodendri 10g, Radix Glycyrrhizae 5g, add 10 times of amount distilled water, soak 0.5h, reflux, extract, 3 times, each 1h, merges 3 times extracting solution, quantitatively filters, being concentrated into 10mL(and being every 1mL water extraction liquid is equivalent to containing crude drug amount 2g), finally adopt after 0.22 μ m filtering with microporous membrane standby.
Above-mentioned seven kinds of compound recipes being made to medicinal liquid and carry out pharmacodynamic experiment, is also the MIC value of utilizing the anti-fowl poultry of measuring in vitro of two times of serial dilution methods of 96 orifice plate mycoplasma, and assay method is the same.The MIC value of the In Vitro Anti fowl poultry mycoplasma of described 7 kinds of compound recipes specifically please be joined table three:
Table three
It should be noted that, MIC1 is the MIC value of culture medium while there is change color for the first time herein, and initial minimal inhibitory concentration, is the Mlc that obviously suppresses the growth and breeding of fowl poultry mycoplasma; The MIC value of MIC2 for determining after 5 days after result of determination for the first time, final minimal inhibitory concentration, is the lasting Mlc that fowl is raiseeed the growth of mycoplasma that effectively suppresses.This is because the mechanism of action that Chinese medicine composition is cured the disease is to utilize the Various Complex effective ingredient of Chinese medicine to regulate organism balance, improve immunity of organisms, rather than all the components directly acts on the object that pathogen reaches cure diseases, the extracorporeal bacteria inhibitor test that utilizes trace liquid diluting method to do Chinese medicine composition whether only can indicate in surveyed Chinese medicine containing some directly antibacterial effective ingredient or containing this antimicrobial component number and the size of antibacterial activity, therefore the MIC value of Chinese medicine composition is often than large many of the MIC value of Chinese medicine extract, conventionally need to judge by twice result of determination the fungistatic effect of Chinese medicine.
At present, both at home and abroad the minimal inhibitory concentration of Chinese medicine composition anti-mycoplasma (MIC) is still sought unity of standard without nothing, therefore be according to judging according to the criterion of similar experiment bibliographical information, comparatively responsive while being MIC≤7.81mg crude drug/mL, when MIC is 7.81～250mg crude drug/mL, be medium sensitivity, be insensitive when MIC > 250mg crude drug/mL.
As shown in Table 2, compound recipe 1～7 body all has the effect of good In Vitro Anti livestock and poultry mycoplasma activity, wherein better with compound recipe 3, compound recipe 5 and compound recipe 6 effects.
The present invention, on the basis of theory of Chinese medical science, provides Chinese medicine extract and the Chinese medicine composition with good anti-fowl poultry mycoplasma activity.Chinese medicine extract and the Chinese medicine composition tool of anti-fowl poultry mycoplasma activity provided by the invention have the following advantages:
1. the Chinese medicine extract of inhibition fowl poultry mycoplasma activity provided by the invention is to extract and make from Chinese medicine, itself and Chinese medicinal compound all have that the traditional Chinese medicine medicinal herbs resource is extensive, toxic and side effects is little, use safety, and be difficult for producing drug resistance, and in the meat of fowl poultry, egg, be difficult for producing the advantage of drug residue.These advantages are all that antibiotic etc is incomparable.
2. Chinese medicine extract provided by the invention and Chinese medicinal compound have heat-clearing and toxic substances removing, heat clearing and damp drying effect, fowl poultry mycoplasma activity is had to obvious inhibition, there is good antipyretic, analgesia, antiinflammatory, cough-relieving, reduce phlegm and antiasthmatic effect, can effectively alleviate the respiratory symptom that fowl poultry mycoplasma causes, the fowl poultry mycoplasma that particularly one or more mycoplasmas in chicken virus mycoplasma, Mycoplasma bovis and mycoplasma ovipneumoniae cause.
3. the application in the fowl poultry mycoplasma disease medicament that above-mentioned Chinese medicine extract and Chinese medicine composition all can be caused by chicken virus mycoplasma, Mycoplasma bovis and mycoplasma ovipneumoniae etc. in preparation has good DEVELOPMENT PROSPECT in the mycoplasma treatment of fowl poultry and prevention.
Those skilled in the art also can make various modifications, interpolation and the replacement in other form and details in the claims in the present invention scope of disclosure and spirit.Certainly, the variations such as various modifications, interpolation and replacement that these are made according to spirit of the present invention, within all should being included in the present invention's scope required for protection.
Claims (9)
1. one kind has the Chinese medicine extract that anti-fowl is raiseeed mycoplasma activity, it is characterized in that: this Chinese medicine extract contains nitidine chloride, ethoxychelerythrine, chelerythrine, Sanguinarine, coptisine, palmatine, any one in epiberberine and enoxolone or multiple, the content range of each material is: nitidine chloride 1-512 μ g/mL, ethoxychelerythrine 1-512 μ g/mL, chelerythrine 1-512 μ g/mL, Sanguinarine 1-512 μ g/mL, coptisine 1-512 μ g/mL, palmatine 1-512 μ g/mL, epiberberine 1-512 μ g/mL and enoxolone 1-512 μ g/mL.
2. the Chinese medicine extract with fowl poultry mycoplasma activity as claimed in claim 1, is characterized in that: the multiple of described Chinese medicine extract is nitidine chloride 1 μ g/mL and ethyoxyl Herba Chelidonii 8 μ g/mL; Nitidine chloride 1 μ g/mL and chelerythrine 4 μ g/mL; Nitidine chloride 2 μ g/mL and Sanguinarine 2 μ g/mL; Nitidine chloride 1 μ g/mL and enoxolone 1 μ g/mL; Any one in these five groups of Chinese medicine extract combinations of nitidine chloride 1 μ g/mL and coptisine 4 μ g/mL.
3. the Chinese medicine extract with anti-fowl poultry mycoplasma activity as claimed in claim 1, it is characterized in that: described enoxolone is from Radix Glycyrrhizae, described coptisine, palmatine and epiberberine are from Rhizoma Coptidis and Cortex Phellodendri, and described nitidine chloride, ethoxychelerythrine, chelerythrine and Sanguinarine are from Radix Zanthoxyli.
4. the Chinese medicine extract with anti-fowl poultry mycoplasma activity as claimed in claim 1, it is characterized in that: described Chinese medicine extract is prepared into the preparation with anti-fowl poultry mycoplasma activity, said preparation is any one dosage form in injection, spray, granule, oral liquid, pill and powder.
5. the Chinese medicine extract with anti-fowl poultry mycoplasma activity as claimed in claim 1, is characterized in that: described Chinese medicine extract is one or more in chicken virus mycoplasma, Mycoplasma bovis and mycoplasma ovipneumoniae in order to the fowl poultry mycoplasma suppressing.
6. one kind has the Chinese medicine composition that anti-fowl is raiseeed mycoplasma activity, it is characterized in that: the crude drug that described Chinese medicine composition comprises following proportioning: at least one of 0-5g in Radix Zanthoxyli 0-10g, Rhizoma Coptidis 0-10g, Cortex Phellodendri 0-10g and Radix Glycyrrhizae, and at least one in Rhizoma Et Radix Baphicacanthis Cusiae 0-30g, Herba Pogostemonis 0-15g, Radix Scutellariae 0-10g, Cortex Dictamni 0-20g, Cortex Pseudolaricis 0-5g, Folium Artemisiae Argyi 0-5g.
7. the Chinese medicine composition with anti-fowl poultry mycoplasma activity as claimed in claim 6, is characterized in that: described Chinese medicine composition is Rhizoma Et Radix Baphicacanthis Cusiae 30g and Radix Zanthoxyli 10g; Rhizoma Et Radix Baphicacanthis Cusiae 30g, Radix Zanthoxyli 10g and Radix Glycyrrhizae 5g; Rhizoma Et Radix Baphicacanthis Cusiae 30g, Radix Zanthoxyli 10g, Rhizoma Coptidis 10g and Cortex Phellodendri 10g; Rhizoma Et Radix Baphicacanthis Cusiae 30g, Radix Zanthoxyli 10g and Radix Scutellariae 10g; Rhizoma Et Radix Baphicacanthis Cusiae 30g, Radix Zanthoxyli 10g and Cortex Dictamni 20g; Rhizoma Et Radix Baphicacanthis Cusiae 30g, Radix Zanthoxyli 10g, Cortex Dictamni 20g, Rhizoma Coptidis 10g and Cortex Phellodendri 10g; Any one in these seven kinds of compound recipes of Rhizoma Coptidis 10g, Radix Scutellariae 10g, Cortex Phellodendri 10g and Radix Glycyrrhizae 5g.
8. the Chinese medicine composition with anti-fowl poultry mycoplasma activity as claimed in claim 6, it is characterized in that: described Chinese medicine composition is prepared into the preparation with anti-fowl poultry mycoplasma activity, said preparation is any one dosage form in injection, spray, granule, oral liquid, pill and powder.
9. the Chinese medicine composition with anti-fowl poultry mycoplasma activity as claimed in claim 6, is characterized in that: described Chinese medicine composition is one or more in chicken virus mycoplasma, Mycoplasma bovis and mycoplasma ovipneumoniae in order to the fowl poultry mycoplasma suppressing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310642170.5A CN103690538B (en) | 2013-12-03 | 2013-12-03 | With the active Chinese medical extract of anti-poultry mycoplasma, Chinese medicine composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310642170.5A CN103690538B (en) | 2013-12-03 | 2013-12-03 | With the active Chinese medical extract of anti-poultry mycoplasma, Chinese medicine composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103690538A true CN103690538A (en) | 2014-04-02 |
| CN103690538B CN103690538B (en) | 2018-07-13 |
Family
ID=50352312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310642170.5A Active CN103690538B (en) | 2013-12-03 | 2013-12-03 | With the active Chinese medical extract of anti-poultry mycoplasma, Chinese medicine composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103690538B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106974983A (en) * | 2016-01-15 | 2017-07-25 | 宁夏大学 | A kind of preparation method for the Chinese medicine compound prescription nasal spray for preventing and treating Mycoplasma bovis disease |
| CN108354936A (en) * | 2018-03-26 | 2018-08-03 | 吉林农业大学 | Sanguinarine is in the application for preparing treatment animal trichinosis drug |
| CN111388527A (en) * | 2020-04-10 | 2020-07-10 | 聊城创新畜禽养殖有限公司 | Preparation for preventing and treating mycoplasma of laying hens and preparation method thereof |
| CN111603514A (en) * | 2020-07-07 | 2020-09-01 | 郑州大学 | Veterinary anti-mycoplasma infection traditional Chinese medicine compound preparation and preparation method and application thereof |
| CN115990233A (en) * | 2022-12-31 | 2023-04-21 | 河南农业职业学院 | Traditional Chinese medicine composition for animal mycoplasma pneumonia and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1729979A (en) * | 2005-08-02 | 2006-02-08 | 浙江万联药业有限公司 | Soft capsule of fibrauretine composition |
| CN101966231A (en) * | 2010-07-26 | 2011-02-09 | 天津生机集团股份有限公司 | Compound pink plumepoppy herb injection for treating calf diarrhea and preparation method thereof |
-
2013
- 2013-12-03 CN CN201310642170.5A patent/CN103690538B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1729979A (en) * | 2005-08-02 | 2006-02-08 | 浙江万联药业有限公司 | Soft capsule of fibrauretine composition |
| CN101966231A (en) * | 2010-07-26 | 2011-02-09 | 天津生机集团股份有限公司 | Compound pink plumepoppy herb injection for treating calf diarrhea and preparation method thereof |
Non-Patent Citations (8)
| Title |
|---|
| 刘晶晶等: "与黄连功能对应的5种药效组分分析", 《辽宁中医药大学学报》 * |
| 吕年胜等: "中药复方制剂对感染鸡毒支原体病鸡的治疗试验", 《山东畜牧兽医》 * |
| 吕年胜等: "中药复方制剂对感染鸡毒支原体病鸡的治疗试验", 《山东畜牧兽医》, vol. 29, 31 December 2008 (2008-12-31), pages 4 - 6 * |
| 周学辉等: "速效肺炎散对羊支原体肺炎疗效观察", 《中兽医医药杂志》 * |
| 孟冬霞等: "中药治疗鸡毒支原体病的研究进展", 《畜牧兽医科技信息》 * |
| 张秀娟: "山羊支原体肺炎的中西医诊治", 《吉林畜牧兽医》 * |
| 徐世洪等: "鸡支原体病得综合防治", 《农技服务》 * |
| 王瑾瑜等: "博落回属植物化学成分的研究进展", 《安徽农学通报》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106974983A (en) * | 2016-01-15 | 2017-07-25 | 宁夏大学 | A kind of preparation method for the Chinese medicine compound prescription nasal spray for preventing and treating Mycoplasma bovis disease |
| CN108354936A (en) * | 2018-03-26 | 2018-08-03 | 吉林农业大学 | Sanguinarine is in the application for preparing treatment animal trichinosis drug |
| CN111388527A (en) * | 2020-04-10 | 2020-07-10 | 聊城创新畜禽养殖有限公司 | Preparation for preventing and treating mycoplasma of laying hens and preparation method thereof |
| CN111603514A (en) * | 2020-07-07 | 2020-09-01 | 郑州大学 | Veterinary anti-mycoplasma infection traditional Chinese medicine compound preparation and preparation method and application thereof |
| CN115990233A (en) * | 2022-12-31 | 2023-04-21 | 河南农业职业学院 | Traditional Chinese medicine composition for animal mycoplasma pneumonia and application thereof |
| CN115990233B (en) * | 2022-12-31 | 2023-10-20 | 河南农业职业学院 | Traditional Chinese medicine composition for animal mycoplasma pneumonia and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103690538B (en) | 2018-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103690538A (en) | Traditional Chinese medicine extract and traditional Chinese medicine composition having poultry and livestock mycoplasma resistant activity | |
| CN101744924B (en) | Multiple-effect Chinese herbal medicine compound of bacterial diseases of turbot | |
| CN102319297B (en) | Traditional Chinese veterinary medicine used for treating livestock, poultry and fish diseases | |
| CN103340973B (en) | Veterinary traditional Chinese medicine composition for treating intestinal bacterial infection as well as preparation method and application thereof | |
| CN104435023A (en) | Traditional Chinese medicine extract and application thereof | |
| CN115531464B (en) | Traditional Chinese medicine composition for resisting mycoplasma caprae pneumonia as well as preparation method and application thereof | |
| CN102805772B (en) | Application of coptis chinensis, amur cork-tree bark, Chinese rhubarb and skullcap dysentery inhibiting particles to preparation of medicines for treating intestinal diseases of poultry, and medicinal composition formed by compounding particles | |
| CN104721337A (en) | Traditional Chinese medicine composition, preparation method and application thereof | |
| CN106619887B (en) | Compound traditional Chinese medicine preparation for inhibiting and killing schbert unicellular bacteria, preparation method and application thereof | |
| CN102579622B (en) | Chinese herbal preparation for treating haemophilusparasuis and preparation method thereof | |
| CN102100730B (en) | Traditional Chinese medicine for improving poultry immunity | |
| CN104147165A (en) | Traditional Chinese medicine for control of animal Escherichia coli disease and preparation method thereof | |
| CN101317879B (en) | Medicament for treating eperythrozoon diseases of cattle, sheep and pig | |
| CN104367633A (en) | Medicine combination with antibacterial and synergically-antibacterial effects, and preparation method and application | |
| CN104367673B (en) | A kind of Chinese medicine composition treating Eimeria species | |
| CN106265894A (en) | A kind of herbal medicine treating fowl bacterial diarrhoea and its production and use | |
| CN103417653B (en) | Veterinary-use compound pure Chinese herbal medicine for treating coccidium and preparation method of oral liquid of same | |
| CN101829257B (en) | Traditional Chinese medicine oral liquid for treating chicken colibacillosis and preparation method thereof | |
| CN115804807B (en) | Traditional Chinese medicine compound composition for preventing and treating mycoplasma ovipneumoniae and preparation method and application thereof | |
| CN112472740B (en) | Chinese herbal medicine compound preparation for preventing and treating cow mastitis and application thereof | |
| CN108743693A (en) | A kind of piglet health care growth promotion Chinese medicine composition, preparation method and applications | |
| CN101411839A (en) | Chinese medicine oral liquid for treating bacterial pneumonia and preparation method thereof | |
| CN104055949B (en) | Traditional Chinese medicine compound composition for the treatment of cancer and preparation method thereof | |
| CN104306629A (en) | Traditional Chinese medicine composition for resisting colibacillosis and preparation method of traditional Chinese medicine composition | |
| CN112426451A (en) | Traditional Chinese medicine composition for treating common infectious disease infection of poultry and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 518057 research building C411, Research Institute of Tsinghua University, Shenzhen, Nanshan District, Guangdong Patentee after: Shenzhen songzhile Biotechnology Co., Ltd Patentee after: RESEARCH INSTITUTE OF TSINGHUA University IN SHENZHEN Address before: 518055 Nanshan District science and Technology Park, Guangdong, South seven road, Shenzhen Institute of Tsinghua University, Shenzhen, C411 Patentee before: SHENZHEN SONGLE BIOTECHNOLOGY Co.,Ltd. Patentee before: RESEARCH INSTITUTE OF TSINGHUA University IN SHENZHEN |